VANCOUVER, BC, May 23, 2025 /CNW/ — GreenPower Motor Company Inc. (NASDAQ: GP) (TSXV: GPV) (the “Company”), a leading manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, announces the results of the Annual General and Special Meeting (AGM) that was held today.

The shareholders elected all of management’s director nominees being Mark Achtemichuk, Fraser Atkinson, Malcolm Clay, Sebastian Giordano, David Richardson and Brendan Riley.

The shareholders also re-approved the Company’s 2022 Equity Incentive Plan and appointed BDO Canada LLP as the Company’s auditors for the ensuing fiscal year.

Following the AGM the Directors of the Company appointed the following officers of the Company for the ensuing year:  Fraser Atkinson – Chairman and Chief Executive Officer, Brendan Riley – President and Michael Sieffert – Chief Financial Officer and Corporate Secretary.

Contact

Fraser Atkinson, CEO 
(604) 220-8048

About GreenPower Motor Company Inc.
GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo vans and a cab and chassis. GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose-built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to www.greenpowermotor.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. © 2025 GreenPower Motor Company Inc. All rights reserved.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenpower-announces-results-of-annual-general-and-special-meeting-and-appointment-of-officers-302464626.html

SOURCE GreenPower Motor Company

IRVING, Texas, May 23, 2025 /PRNewswire/ — Caris Life Sciences® (“Caris”), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caris has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “CAI.”

BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC will act as lead book-running managers for the proposed offering. Citigroup will also act as a book-running manager for the proposed offering. TD Cowen, Evercore ISI and Guggenheim Securities will act as additional book-running managers for the proposed offering. BTIG and Wolfe | Nomura Alliance will act as co-managers for the proposed offering.

The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: dg.prospectus_requests@bofa.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com; or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282 or by email: prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-files-registration-statement-for-proposed-initial-public-offering-302464597.html

SOURCE Caris Life Sciences

INDIANAPOLIS, May 23, 2025 /PRNewswire/ — This Memorial Day Weekend, the spotlight won’t only be on speed—it’ll be on saving lives. ZERO Prostate Cancer (ZERO), the nation’s leading advocacy and support organization for prostate cancer, is proud to announce its powerful presence across America’s most iconic motorsports stages: the Indianapolis 500 and NASCAR’s Coca-Cola 600 and BetMGM 300. The message? Veterans are twice as likely to face prostate cancer—and early detection saves lives.

In partnership with Juncos Hollinger Racing, ZERO’s logo will be featured on two cars in the 1009th Running of the Indianapolis 500—the world’s biggest single-day sporting event—on Sunday, May 25 at 12:45 PM ET (FOX). ZERO’s logo will appear on the cars of INDYCAR drivers Conor Daly and Sting Ray Robb.

At the same time, ZERO and partner AstraZeneca are making waves in NASCAR’s patriotic tribute weekend with two ZERO-branded vehicles:

No. 66 Ford Mustang driven by Josh Bilicki in the Coca-Cola 600 (Sunday, May 25 at 6:00 PM ET on Amazon Prime)No. 53 Chevrolet Camaro driven by JJ Yeley in the BetMGM 300 (Saturday, May 24 at 1:00 PM ET on The CW)

Together, this high-octane campaign is bringing national visibility to a deadly disease that claims a man’s life every 15 minutes in the U.S.—and hits military Veterans at double the rate of the general population.

“This weekend isn’t just about racing—it’s about saving lives,” said Josh Bilicki. “If even one man schedules a PSA test because of this message, we’ve done our job.”

“As a 48-year-old and part of a sport deeply rooted in the Veteran community, this message really hits home,” said JJ Yeley. “We’re proud to be racing for something bigger than ourselves.”

“Prostate cancer has become too big to ignore,” said Courtney Bugler, President and CEO of ZERO Prostate Cancer. “More than 3 million men in the U.S. are living with this disease, and too many don’t even know they’re at risk—especially our Veterans. Memorial Day is about honoring those we’ve lost, and at ZERO, we’re also fighting to save the ones still here.”

This campaign aligns with ZERO’s bold initiative to save 100,000 lives by 2035, with targeted efforts toward Veterans, Black men, and rural communities—the populations most impacted by the disease.

“It’s time to race toward solutions,” said Daniele Paone, VP US, GYN/GU Cancer Franchise, AstraZeneca. “We’re proud to team up with ZERO and the motorsports community to drive awareness where it’s urgently needed.”

For nearly 30 years, ZERO has been on the front lines of the prostate cancer fight, providing education, support, and advocacy to patients and families. This Memorial Day, from Indy to Charlotte, the message is unmistakable: know your risk, talk to your doctor and get screened.

Watch the Races Live:

BetMGM 300 (Xfinity Series): Saturday, May 24 – 1:00 PM ET on The CWCoca-Cola 600 (Cup Series): Sunday, May 25 – 6:00 PM ET on Amazon PrimeIndianapolis 500 (IndyCar): Sunday, May 25 – 12:45 PM ET on FOX

Learn more and find resources at ZEROcancer.org

MEDIA CONTACT:
Steph Johnson
Vice President, Communications
ZERO Prostate Cancer
steph.johnson@zerocancer.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/indy-500-stars-join-forces-with-zero-prostate-cancer-to-put-veterans-health-in-the-spotlight-at-memorial-day-weekend-races-302464599.html

SOURCE ZERO Prostate Cancer